All In Biotech

Drug Trial Radar · NCT00915525

Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Last checked: Nov 20, 2026Latest source record: Apr 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

829

Actual

Start

Feb 1, 2010

Primary completion

Aug 5, 2014

Study completion Aug 5, 2014

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 8, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.

Conditions

  • Overactive Bladder
  • Urinary Incontinence

Interventions

  • botulinum toxin Type ABiological

    Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 1
  2. Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 2
  3. Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 3
  4. Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 4
  5. Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 5
  6. Change From Study Baseline in the Daily Average Number of Urinary Incontinence EpisodesTime frame: Study Baseline, Week 12 Treatment Cycle 6
  7. Percentage of Patients With a Positive Response on the 4-Point Treatment Benefit Scale (TBS)Time frame: Week 12 Treatment Cycle 1
  8. Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 2
  9. Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 3
  10. Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 4
  11. Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 5
  12. Percentage of Patients With a Positive Response on the 4-Point TBSTime frame: Week 12 Treatment Cycle 6

Locations

8 sites in 8 countries. Site status is shown where the registry gives one.

  • Site not named

    Newport Beach, California

  • Site not named

    Ghent, Belgium

  • Site not named

    Victoria, British Columbia, Canada

  • Site not named

    Prague, Czechia

  • Site not named

    Tübingen, Germany

  • Site not named

    Warsaw, Poland

  • Site not named

    Moscow, Russia

  • Site not named

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.